Cellectar Biosciences Inc stock is traded at $1.21, with a volume of 21,471. It is down -0.82% in the last 24 hours and down -15.38% over the past month. Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Previous Close:
$1.22
Open:
$1.26
24h Volume:
21,471
Relative Volume:
0.24
Market Cap:
$12.15M
Revenue:
-
Net Income/Loss:
-$20.84M
P/E Ratio:
-
EPS:
-$7.37
Net Cash Flow:
-$18.59M
1W Performance:
+5.22%
1M Performance:
-15.38%
6M Performance:
-58.56%
1Y Performance:
-65.43%
1-Day Range:
$1.19$1.30
1-Week Range:
$1.13$1.32
52-Week Range:
$1.11$4.70
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences IncSector
HealthcareIndustry
BiotechnologyPhone
(608) 441-8120Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS